UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 19, 2024
(Exact name of registrant as specified in its charter)
|
|
|
|
||
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (888 ) 997-8732
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
||
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
Streamline Health Solutions, Inc. (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”) on September 19, 2024. Proxies for the Special Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition to the Board’s proposals. At the Special Meeting, the Company’s stockholders voted upon two proposals. The proposals are described in detail in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on August 19, 2024.
As of the record date for the Special Meeting, there were 63,324,103 shares of the Company's common stock, par value $0.01 per share, outstanding and entitled to vote on each matter presented for vote at the Special Meeting. At the Special Meeting, 51,411,267 shares of common stock, or approximately 81%, of the outstanding shares of common stock, were represented in person or by proxy. A brief description and the final vote results for each proposal follow.
|
1.
|
Approval of an amendment to the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s issued and outstanding shares of common stock at a ratio of any whole number between 1-for-5 and 1-for-15, at any time prior to October 4, 2024, with the exact ratio to be set within that range at the discretion of the Board, without further approval or authorization of the Company’s stockholders:
|
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|||
|
50,952,491
|
412,639
|
46,137
|
─
|
As a result, the proposal was approved.
|
2.
|
Approval of the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt Proposal 1:
|
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|||
|
50,844,291
|
540,375
|
26,601
|
─
|
As a result, the proposal was approved.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
EXHIBIT
NUMBER
|
DESCRIPTION
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
STREAMLINE HEALTH SOLUTIONS, INC.
|
||
|
Date: September 19, 2024
|
By:
|
/s/ Bryant J. Reeves, III
|
|
Bryant J. Reeves, III
|
||
|
Chief Financial Officer
|
||